Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Blueprint Medicines Corp
(NQ:
BPMC
)
95.70
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Blueprint Medicines Corp
< Previous
1
2
3
4
5
6
Next >
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
October 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In...
Via
Benzinga
Pfizer's CEO Wants to Go Shopping: 3 Potential Companies on His Radar
August 05, 2021
Projecting over $33 billion in COVID-19 vaccine revenue alone in 2021, CEO Albert Bourla wants to beef up Pfizer's pipeline.
Via
The Motley Fool
Topics
Earnings
Exposures
COVID-19
Financial
Blueprint Medicines: Q2 Earnings Insights
July 29, 2021
Shares of Blueprint Medicines (NASDAQ:BPMC) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share were up 18.42% year over year to...
Via
Benzinga
Analyst Ratings for Blueprint Medicines
June 17, 2021
Blueprint Medicines (NASDAQ:BPMC) has observed the followi...
Via
Benzinga
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
October 24, 2021
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...
Via
Benzinga
Exposures
Product Safety
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
June 20, 2021
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
July 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
July 25, 2021
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
June 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,...
Via
Benzinga
Exposures
COVID-19
Product Safety
The Week Ahead In Biotech: Takeda, Blueprint Medicines, Orphazyme, Eton On The Radar Ahead Of FDA Decisions, IPOs
June 13, 2021
Biotech stocks extended their gains in the week ended June 11, supported by the broader market strength and some stock-specific moves. The biggest biotech news of the week came in...
Via
Benzinga
Exposures
Product Safety
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
June 01, 2021
The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive...
Via
Benzinga
Exposures
Product Safety
Recap: Blueprint Medicines Q1 Earnings
April 29, 2021
Shares of Blueprint Medicines (NASDAQ:BPMC) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share were up 18.48% over the past...
Via
Benzinga
1 Cancer Stock to Buy and Hold for the Next Decade
April 17, 2021
Blueprint Medicines is setting itself up to become the leader in precision oncology.
Via
The Motley Fool
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
April 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:...
Via
Benzinga
The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
April 10, 2021
Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of...
Via
Benzinga
Exposures
Product Safety
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
April 24, 2021
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.